M. Ghielmini et al., Differential toxicity of anticancer drugs on late (GM-CFC) and early (LTC-IC) hemopoietic progenitors in vitro, CELL BIOL T, 15(6), 1999, pp. 395-404
The clinical hematological toxicity of cytotoxic drugs can be acute, with a
nadir of neutrophil count after 2 weeks and recovery the following week, o
r subacute, with a nadir of neutrophil count after 3 weeks and recovery in
the following 2-3 weeks. The explanation usually given for this difference
is that drugs in the first group are more toxic to mature hemopoietic precu
rsors, while drugs of the second type are more toxic to undifferentiated ce
lls. In an attempt to verify this hypothesis, we compared in vitro the effe
ct of toxic doses of etoposide and tallimustine as representatives of drugs
with acute toxicity, and of BCNU, melphalan, and carzelesin as representat
ives of drugs with subacute toxicity. Their effects were studied separately
on more differentiated and earlier progenitors represented by granulocyte-
macrophage colony-forming cells (GM-CFC) and long-term culture-initiating c
ells (LTC-IC), respectively. Etoposide, melphalan, BCNU, and carzelesin sho
wed higher toxicity in differentiated than in early precursors: the concent
ration of drug inhibiting 70% (ID70) of GM-CFC inhibited only by 10-40% the
growth of LTC-IC. Tallimustine, in contrast, inhibited both GM-CFC and LTC
-IC at comparable levels. These results do not correspond to the clinical p
attern of myelotoxicity observed for those drugs. We conclude that the diff
erential effects of antitumor drugs on later (GM-CFC) or earlier (LTC-IC) h
emopoietic precursors may not represent a valid model for the pattern of my
elotoxicity observed in humans.